Petach Tikva, Israel

Yitzhak Lerner

This inventor holds 1 USPTO granted patent. Top assignee: Teva Pharmaceutical Industries Limited. Active years: 2002.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Yitzhak Lerner Revolutionizing Pharmaceutical Formulations

Introduction: Yitzhak Lerner, a brilliant inventor hailing from Petach Tikva, IL, has made significant contributions to the field of pharmaceuticals through his groundbreaking patents and innovative research.

Latest Patents: Yitzhak Lerner holds one impactful patent titled "Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates." This patent introduces a compacted pharmaceutical composition that expands in gastric fluid, ensuring prolonged retention in the stomach and effective delivery of therapeutic bis-phosphonates.

Career Highlights: Yitzhak Lerner is associated with Teva Pharmaceutical Industries Limited, a renowned pharmaceutical company known for its cutting-edge research and development efforts. Within this esteemed organization, Yitzhak has showcased his expertise in formulating advanced drug delivery systems.

Collaborations: Yitzhak Lerner's dedication to innovation is further exemplified through his collaborations with accomplished coworkers such as Moshe Flashner-Barak and Vered Rosenberger. Together, they have worked synergistically to advance pharmaceutical technologies and improve patient outcomes.

Conclusion: In conclusion, Yitzhak Lerner's pioneering work in pharmaceutical formulations stands as a testament to his ingenuity and commitment to advancing healthcare solutions. His innovative approach to drug delivery systems has the potential to revolutionize the industry and benefit countless individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…